Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

180 Life Sciences Corp (ATNF)

180 Life Sciences Corp (ATNF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,403
  • Shares Outstanding, K 1,027
  • Annual Sales, $ 0 K
  • Annual Income, $ -19,940 K
  • EBIT $ -6 M
  • EBITDA $ -4 M
  • 60-Month Beta 0.23
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.65

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.21 +1.36%
on 11/21/24
5.90 -62.03%
on 10/25/24
-2.73 (-54.93%)
since 10/21/24
3-Month
1.16 +93.10%
on 10/08/24
17.75 -87.38%
on 10/16/24
+0.33 (+17.28%)
since 08/21/24
52-Week
1.16 +93.10%
on 10/08/24
17.75 -87.38%
on 10/16/24
-4.60 (-67.25%)
since 11/21/23

Most Recent Stories

More News
180 Life Sciences Corp. Interim CEO, Blair Jordan, Issues Letter to Stockholders; Provides Update on Newly Acquired Gaming Technology Platform

PALO ALTO, CA / ACCESSWIRE / October 16, 2024 / 180 Life Sciences Corp. (NASDAQ:ATNF)("180" or the "Company"), today released the following letter to stockholders from its Interim Chief Executive Officer,...

ATNF : 2.28 (-2.56%)
Elicit Plant Appoints Pam Marrone and Johan de Saegher on Its Board of Directors

Elicit Plant, an agricultural biotechnology company specialized in crops’ resistance to water stress based on a phytosterol-based technology platform, announced today it has appointed Dr. Pam Marrone...

ATNF : 2.28 (-2.56%)
Newman Ferrara LLP Investigating Officers and Directors of 180 Life Sciences Corp. (ATNF)

Newman Ferrara LLP announced today that it has an ongoing investigation into actions taken by officers and directors of KBL Merger Corp. IV (“KBL”), a special purpose acquisition company (“SPAC”)...

ATNF : 2.28 (-2.56%)
Pre-Market Brief: Stocks Climb As Recession Fears Ease, China Reopens Borders

March S&P 500 futures (ESH23) are trending up +0.72% this morning after three major U.S. benchmark indices closed higher on Friday as market participants digested a deluge of economic data against rate...

ESH23 : 3,957.05s (-0.09%)
ATNF : 2.28 (-2.56%)
AMC : 4.49 (+1.13%)
EC : 8.19 (+1.36%)
AMTI : 0.2630 (-14.30%)
PTRA : 0.0670 (-25.56%)
180 Life Sciences Announces That the University of Oxford Has Been Awarded a Grant From the National Institute for Health and Care Research in the U.K. to Conduct a Clinical Trial in Post Operative Delirium/Cognitive Deficit in a Jointly Funded Program

PALO ALTO, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage...

ATNF : 2.28 (-2.56%)
180 Life Sciences Corp. Announces $6.5 Million Registered Direct Offering

PALO ALTO, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage...

ATNF : 2.28 (-2.56%)
180 Life Sciences Corp. Issues Letter to Stockholders

PALO ALTO, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the "Company"), a clinical-stage...

ATNF : 2.28 (-2.56%)
180 Life Sciences Provides Update on Correspondence Received from U.K. and U.S. Regulatory Authorities on Pathway for a Therapy That Could Prevent Progression of Early-Stage Dupuytren’s Disease

PALO ALTO, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage...

ATNF : 2.28 (-2.56%)
180 Life Sciences Begins Consultations with UK and US Regulatory Authorities on Pathway for a Therapy that Could Prevent Progression of Early-Stage Dupuytren’s Disease

PALO ALTO, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage...

ATNF : 2.28 (-2.56%)
180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytren’s Disease Study Results in The Lancet Rheumatology

The study achieved the primary endpoint of reduction in nodule hardness at 12 months and secondary endpoint of reduction in nodule size at multiple time...

ATNF : 2.28 (-2.56%)

Business Summary

180 Life Sciences Corp. is a clinical-stage biotechnology company. It is focused on the development of novel drugs for unmet needs in inflammatory diseases, fibrosis and pain. 180 Life Sciences Corp., formerly known as KBL Merger Corp. IV, is based in MENLO PARK, Calif.

See More

Key Turning Points

3rd Resistance Point 2.57
2nd Resistance Point 2.51
1st Resistance Point 2.42
Last Price 2.28
1st Support Level 2.27
2nd Support Level 2.21
3rd Support Level 2.12

See More

52-Week High 17.75
Fibonacci 61.8% 11.41
Fibonacci 50% 9.45
Fibonacci 38.2% 7.50
Last Price 2.28
52-Week Low 1.16

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar